Linked Life Data

10069489

Source:http://linkedlifedata.com/resource/pubmed/id/10069489

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1999-3-17
pubmed:abstractText
Parasympathetic hyperactivity is found in some infants presenting faint episodes and could be responsible of certain Sudden Infant Death Syndrome cases. Therefore it was interesting to look for a noninvasive biochemical indicator of parasympathetic activity. A parasympaticomimetic syndrome associated with muscarinic receptor stimulation, which has been followed during 48 h, was obtained in the awake rat by reserpine injection (6.25 mg/kg at T0 and T24h), and a model of prolonged parasympatholytic syndrome, by administration of diphemanil-methylsulfate (DPMS), a muscarinic receptor inhibitor, in drinking water (mean daily dosis: 150 mg/kg). Significant bradycardia and tachycardia were respectively observed. In the reserpine-treated rats we found significantly increased cyclic guanosylmonophosphate (cGMP) urinary excretion between T24h and T48h, when compared with vehicle-treated controls (+87% in one experiment, +135% in the other, when expressed in pmol/microg creatinine); norepinephrine urinary excretion between T24h and T48h was decreased (-44%); the increase in cGMP urinary excretion was not significantly modified by the NO-synthase inhibitor, L-nitroarginine-methyl-ester. In the DPMS-treated rats, we observed a significantly decreased cGMP (-20%) and increased norepinephrine urinary excretion (+61%). Thus cGMP excretion varied in opposite directions in the reserpine- and DPMS-treated rats. The link between these modifications in cGMP excretion and muscarinic receptor stimulation or blockade has still to be fully demonstrated. Urinary cGMP excretion could be tested as screening parameter in infants at risk of faint episodes associated with bradycardia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0024-3205
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
113-23
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:10069489-Animals, pubmed-meshheading:10069489-Autonomic Nervous System Diseases, pubmed-meshheading:10069489-Cyclic GMP, pubmed-meshheading:10069489-Dose-Response Relationship, Drug, pubmed-meshheading:10069489-Heart Rate, pubmed-meshheading:10069489-Hemodynamics, pubmed-meshheading:10069489-Male, pubmed-meshheading:10069489-Muscarinic Agonists, pubmed-meshheading:10069489-Muscarinic Antagonists, pubmed-meshheading:10069489-NG-Nitroarginine Methyl Ester, pubmed-meshheading:10069489-Nitric Oxide, pubmed-meshheading:10069489-Nitric Oxide Synthase, pubmed-meshheading:10069489-Norepinephrine, pubmed-meshheading:10069489-Parasympathetic Nervous System, pubmed-meshheading:10069489-Parasympatholytics, pubmed-meshheading:10069489-Piperidines, pubmed-meshheading:10069489-Rats, pubmed-meshheading:10069489-Rats, Sprague-Dawley, pubmed-meshheading:10069489-Reserpine, pubmed-meshheading:10069489-Syndrome
pubmed:year
1999
pubmed:articleTitle
Cyclic guanosylmonophosphate urinary excretion in parasympathicomimetic or parasympatholytic syndromes induced by reserpine or diphemanil-methylsulfate.
pubmed:affiliation
Equipe de Recherches sur la Biochimie et la Pharmacologie des Vaisseaux et du Rein, Faculté de Médecine, Université de Paris V & VI, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't